Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. (Q53524637)

15 May 2018

title

Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. (English)

1 reference

15 May 2018

0 references

1 reference

1 reference

Green CP

1

1 reference

15 May 2018

Porter CB

series ordinal

2

1 reference

15 May 2018

Bresnahan DR

series ordinal

3

1 reference

15 May 2018

Spertus JA

series ordinal

4

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 April 2000

1 reference

15 May 2018

number of pages

11

1 reference

Journal of the American College of Cardiology

inferred from page(s)

published in

1 reference

15 May 2018

volume

35

1 reference

15 May 2018

issue

5

1 reference

15 May 2018

page(s)

1245-1255

1 reference

15 May 2018

Measuring health-related quality of life

cites work

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Monitoring the quality of life in patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Development and testing of a new measure of health status for clinical trials in heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Depression following myocardial infarction. Impact on 6-month survival.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Depression and 18-month prognosis after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Quality of life on enalapril after acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

A controlled trial of digoxin in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(00)00531-3

7 January 2021

10.1016/S0735-1097(00)00531-3

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018